NASDAQ:ABMD

Abiomed Stock Forecast, Price & News

$325.09
+6.52 (+2.05 %)
(As of 06/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$313.73
$326.35
50-Day Range
$262.71
$351.17
52-Week Range
$234.39
$387.40
Volume297,009 shs
Average Volume306,985 shs
Market Capitalization$14.73 billion
P/E Ratio65.94
Dividend YieldN/A
Beta1.29
30 days | 90 days | 365 days | Advanced Chart
Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Abiomed and its competitors with MarketBeat's FREE daily newsletter.


Abiomed logo

About Abiomed

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.47 out of 5 stars

Medical Sector

632nd out of 2,105 stocks

Surgical & Medical Instruments Industry

60th out of 174 stocks

Analyst Opinion: 1.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Abiomed (NASDAQ:ABMD) Frequently Asked Questions

Is Abiomed a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abiomed in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Abiomed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares.
View analyst ratings for Abiomed
or view top-rated stocks.

What stocks does MarketBeat like better than Abiomed?

Wall Street analysts have given Abiomed a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Abiomed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Abiomed's next earnings date?

Abiomed is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Abiomed
.

How were Abiomed's earnings last quarter?

Abiomed, Inc. (NASDAQ:ABMD) issued its quarterly earnings results on Wednesday, April, 28th. The medical equipment provider reported $1.24 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.10 by $0.14. The medical equipment provider had revenue of $241.30 million for the quarter, compared to the consensus estimate of $231.13 million. Abiomed had a trailing twelve-month return on equity of 14.99% and a net margin of 26.61%. The firm's quarterly revenue was up 16.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.70 EPS.
View Abiomed's earnings history
.

How has Abiomed's stock price been impacted by COVID-19?

Abiomed's stock was trading at $151.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ABMD stock has increased by 115.1% and is now trading at $325.09.
View which stocks have been most impacted by COVID-19
.

What guidance has Abiomed issued on next quarter's earnings?

Abiomed updated its FY 2022 earnings guidance on Thursday, May, 6th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $990 M-$1.03 billion, compared to the consensus revenue estimate of $998.13 million.

What price target have analysts set for ABMD?

5 brokers have issued 1 year target prices for Abiomed's shares. Their forecasts range from $245.00 to $425.00. On average, they anticipate Abiomed's stock price to reach $351.25 in the next year. This suggests a possible upside of 8.0% from the stock's current price.
View analysts' price targets for Abiomed
or view top-rated stocks among Wall Street analysts.

Who are Abiomed's key executives?

Abiomed's management team includes the following people:
  • Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 54, Pay $1.68M)
  • Mr. Todd A. Trapp, CFO & VP (Age 50, Pay $800.98k)
  • Dr. David M. Weber, Sr. VP & COO (Age 60, Pay $752.48k)
  • Mr. Michael G. Howley, VP & GM of Global Sales (Age 57, Pay $522.56k)
  • Mr. Andrew J. Greenfield, VP & Chief Commercial Officer (Age 48, Pay $547.39k)
  • Dr. Thorsten Siess Ph.D., VP & CTO
  • Ms. Ingrid Goldberg Ward, Director of Investor Relations
  • Mr. Marc A. Began, VP, Gen. Counsel & Sec. (Age 54)
  • Sarah Karr, Communications Mang.
  • Ms. Karen Mahoney, Head of Global HR

What is Michael R. Minogue's approval rating as Abiomed's CEO?

96 employees have rated Abiomed CEO Michael R. Minogue on Glassdoor.com. Michael R. Minogue has an approval rating of 72% among Abiomed's employees.

Who are some of Abiomed's key competitors?

What other stocks do shareholders of Abiomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Square (SQ), Netflix (NFLX), Adobe (ADBE) and salesforce.com (CRM).

What is Abiomed's stock symbol?

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

Who are Abiomed's major shareholders?

Abiomed's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.14%), Baillie Gifford & Co. (7.61%), Primecap Management Co. CA (4.24%), Renaissance Technologies LLC (3.94%), Brown Capital Management LLC (3.54%) and William Blair Investment Management LLC (2.07%). Company insiders that own Abiomed stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Martin P Sutter, Michael R Minogue and Paul Thomas.
View institutional ownership trends for Abiomed
.

Which major investors are selling Abiomed stock?

ABMD stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, Renaissance Technologies LLC, Bessemer Group Inc., Primecap Management Co. CA, Ameriprise Financial Inc., Waddell & Reed Financial Inc., Morgan Stanley, and Los Angeles Capital Management LLC. Company insiders that have sold Abiomed company stock in the last year include Andrew J Greenfield, Dorothy E Puhy, Martin P Sutter, Michael R Minogue, and Paul Thomas.
View insider buying and selling activity for Abiomed
or view top insider-selling stocks.

Which major investors are buying Abiomed stock?

ABMD stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., William Blair Investment Management LLC, Credit Suisse AG, Chicago Capital LLC, Gilder Gagnon Howe & Co. LLC, Janus Henderson Group PLC, Verde Servicos Internacionais S.A., and Prudential Financial Inc..
View insider buying and selling activity for Abiomed
or or view top insider-buying stocks.

How do I buy shares of Abiomed?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abiomed's stock price today?

One share of ABMD stock can currently be purchased for approximately $325.09.

How much money does Abiomed make?

Abiomed has a market capitalization of $14.73 billion and generates $847.52 million in revenue each year. The medical equipment provider earns $225.52 million in net income (profit) each year or $4.94 on an earnings per share basis.

How many employees does Abiomed have?

Abiomed employs 1,725 workers across the globe.

Does Abiomed have any subsidiaries?

The following companies are subsidiares of Abiomed: ABD Holding Company, ABIOMED Athlone Ltd, ABIOMED Australia Pte. Ltd, ABIOMED Europe, ABIOMED Japan KK, ABIOMED Limited, ABIOMED R&D, ABIOMED SARL, ABIOMED Singapore Pte. Ltd, AIS GmbH Aachen Innovative Solutions, ECP Entwicklungsgesellschaft mbH, and Impella Cardiosystems.

When was Abiomed founded?

Abiomed was founded in 1981.

What is Abiomed's official website?

The official website for Abiomed is www.abiomed.com.

Where are Abiomed's headquarters?

Abiomed is headquartered at 22 CHERRY HILL DR, DANVERS MA, 01923.

How can I contact Abiomed?

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]


This page was last updated on 6/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.